In people with ALL, something goes wrong with a type of blood stem cell called a lymphoblast. Instead of maturing into fully functioning lymphocytes — important immune-system cells — the lymphoblasts ...
The U.S. FDA has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified ...
The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...
The US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel) to treat ...
Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...
Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.
The U.S. FDA has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback